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patients randomized to SIR/TAC received one year of SIR
following HCT, while MTX/TAC patients received MTX on
days 1, 3, 6, and 11. QOL was assessed with the Functional
Assessment of Cancer Therapy e Bone Marrow Transplant
Treatment Outcome Index (TOI) prior to HCT and day 30, 90,
180, 270, and 360 following HCT. Random effects models
were used to examine longitudinal trajectories of QOL
between day 30 and 360 by study arm, controlling for
baseline TOI scores.
Results: A total of 74 patients were enrolled (37 per study
arm); all contributed data to these analyses. Analyses indi-
cated that the MTX/TAC group showed greater improvement
in TOI scores over time compared to the SIR/TAC group
(P ¼ .02); by day 360, the average difference between groups
was 7.18 points (P ¼ .03). This effect continued to be signiﬁ-
cant (P < .01) when controlling for clinical differences
between groups, including acute GVHD, chronic GVHD, and
anemia. Exploratory analyses of subscales comprising the
TOI [i.e., Physical Well-Being (PWB), Functional Well-Being
(FWB), BMT Scale (BMTS)] indicated that group differences
were due to greater improvement in PWB in the MTX/TAC
group (P ¼ .02). Additional exploratory analyses of items on
the PWB scale indicated that members of the SIR/TAC arm
were more likely to endorse a lack of energy and nausea over
time (ps.01). Study arm differences on these items per-
sisted when controlling for acute GVHD, chronic GVHD, and
anemia (ps<.01).
Conclusions: Data from the current study indicate that SIR/
TAC is associated with less improvement in QOL in the ﬁrst
year post-HCT compared to MTX/TAC. This difference is not
attributable to other potential clinical differences between
study arms, including acute and chronic GHVD and anemia.
Differences in QOL appear to result in part from greater
fatigue and nausea in participants treated with SIR, which
was administered throughout the one year follow-up period.77
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Background: Characterisation of late effects in children
undergoing hematopoietic stem cell transplant (HSCT) for
non-malignant diseases is challenging due to the small
numbers of rare diseases, variations in cancer susceptibility
and organ toxicity associated with primary diagnosis as well
as non-uniform clinical practice. In addition, limited follow-
up in previous studies may have underestimated the risk of
second cancers and late deaths in this group of transplant
recipients. Our study used population-based registry data to
determine the risk of malignancy and late mortality inpediatric patients transplanted for non-malignant
conditions.
Methods: 318 Australian allogeneic transplant recipients
aged less than 15 years, treated from 1982-2007 for non-
malignant conditions, were identiﬁed from children's
hospitals and the Australasian Bone Marrow Transplant
Recipient Registry (ABMTRR). Clinical and demographic data
were obtained from the ABMTRR and medical records.
Linkage with the Australian Cancer Database and National
Death Index was performed to identify all primary invasive
cancers and deaths in this cohort. Standardised incidence
ratios (SIRs) were generated for second malignancies and
deaths in 2-year survivors.
Results: Indications for HSCT included; primary immuno-
deﬁciencies (n¼130), aplastic anemia (SAA, n¼71), inherited
marrow failure syndromes (n¼51), thalassemia (n¼14) and
hemophagocytic lymphohistiocytosis (n¼14). Over two
thirds of recipients weremale (69%), while the median age at
transplant was 3 years (range 0-14y) A total of 43 patients
received radiation therapy as part of their conditioning
regimen.
Six malignancies were identiﬁed in male patients with
various diseases including Fanconi Anemia (2), Severe
Aplastic Anemia (1), severe combined immune deﬁciency
(1), Thalassemia (1) and chronic granulomatous disease
(n¼1). The most common second cancer was squamous cell
carcinoma of the tongue. Overall there was a 15-fold
increased risk of malignancy compared to the Australian
general population (SIR¼15.37, 95%CI¼6.91-34.21).
Two thirds of patients (62%) survived for more than 2
years after HSCT, while the cumulative incidence of late
death was 2.1% at 5 years from HSCT and 6.3% at 10 years
from HSCT. Overall, the rate of death was 17 times greater
than expected compared to the general population, with
cancer being the most common cause of death.
Conclusion: These ﬁndings show an increased rate of
malignancy and late death in Australian pediatric patients
transplanted for non-malignant conditions compared to the
general population. This conﬁrms the need for long term
surveillance to maximize the early detection of subsequent
malignancies, which may occur a decade or more after
HSCT.78
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Background: Increasing indications for transplant and
improvements in early transplant outcomes have lead to an
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knowledge regarding late effects comes from studies in adult
recipients or hospital based studies where duration or reli-
ability of follow-up data is limited. The aim of our study was
to examine the risk of second malignancy and late mortality
in a population-based cohort of pediatric recipients of allo-
geneic hematopoietic stem cell transplant (HSCT) in
Australia.
Methods: Australian pediatric allogeneic HSCT recipients
aged less than 15 years and treated for a hematological
malignancy from 1982-2007, were identiﬁed from pediatric
hospitals and the Australasian Bone Marrow Transplant
Recipient Registry (ABMTRR). Patient records were linked to
records held by the Australian Cancer Database (ACD) and
National Death Index to determine second cancers and
deaths in the cohort. Standardized rates (SIRs & SMRs) and
risk factors were characterised for second malignancies
following HSCT and late deaths (deaths occurring 2 or more
years after HSCT).
Results: Second cancers were observed in 17 of the 674
(2.5%) HSCT recipients with a primary cancer diagnosis
recorded on the ACD. Thyroid cancer was the most
common second cancer observed (n¼8) followed by brain
tumours (n¼4). The rate of second cancers occurring after
HSCT was 20 times higher than expected based on rates in
the age-, sex- and calendar-year matched general pop-
ulation (SIR¼20.33, 95% CI¼12.64-32). Total body irradia-
tion was associated with a 4-fold increased risk of
secondary malignancy, while non-Hodgkin lymphoma
patients were 7 times more likely to develop a second
malignancy compared to acute lymphoblastic leukaemia
patients.
While the overall rate of late death was 36 times greater
than the rate seen in the age-, sex- and calendar-year
matched general population (SMR¼35.93, 95%CI¼26.74-
48.29), rates of death returned to levels similar to the general
population 10 years after HSCT.
Conclusions: This is the ﬁrst study to use population-based
registry data to determine the risk of second cancer and late
death in pediatric patients with a hematologic cancer treated
by allogeneic HSCT. The increased risk of second cancer and
late deaths in this population highlights the importance of
long-term follow up, surveillance and early detection of
second cancer.Table
Associations between HCT-CI risk groups and dichotomized outcomes of
QOL among 398 long-term HCT survivors
Dichotomized outcomes
based on standard cutoffs
from population norms
HCT-
CI 0
HCT-
CI 1-2
HCT-
CI 3
Adjusted
P-trend
% % %
SCL-90-R depression 20 >1.74 3 7 9 0.04
CTXD distress >1.11 15 21 23 0.04
ESSI social support < 13.8 11 13 21 0.02
SRCI general health score > 2 31 38 60 0.0005
Logistic regression model: adjusted for age, gender diagnoses, disease
status, CMV sero-status, conditioning intensity, doner type, and stem cell
source + self-reported race, location per state, rural vs. urban, and years post
HCT + relapse.79
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Whether pre-transplant comorbidities are associated
with QOL after allogeneic HCT is unknown.We used the HCT-
comorbidity index (CI) in order to investigate possibleassociations of baseline comorbidities with different
domains of QOL among long-term survivors.
All survivors >17 years of age, who were 3-18 years after
HCT for hematological malignancy, without active cancers
for 2 years, and with internet access were eligible for the
study and hence were approached by mail for participation.
Assessment was conducted with an online survey that
collected information on socioeconomic status, the Short-
Form Health Survey (SF-36), Fatigue Symptom Inventory
(FSI), Symptom Check List-90-Revised (SCL-90-R) for
depression, Cancer and Treatment Distress (CTXD) scale,
ENRICHD Social Support Instrument (ESSI), Social Activity
Log (SAL), and self-reported comorbidity index (SR-CI) for
general health.
Of 1,775 participants approached for the study, 775 were
eligible, consented and completed the assessments, of whom
588 were recipients of allogeneic HCT, of whom 398 were
given HLA-matched grafts and contributed to this study.
Median age at HCT was 43 (3-76) years and median time
from HCT was 7.5 (3.1-17.2) years. Diagnoses were mostly
myeloid (83%) or lymphoid (16%) malignancies. Baseline
HCT-CI scores were 0 vs. 1-2 vs. 3 in 47%, 35%, and 18% of
survivors, respectively. High-intensity conditioning regi-
menswere used in 88% of the survivors, and grafts were from
related donors in 55% of survivors. Rate of post-HCT relapse
was 11%.
Linear and logistic regression models were adjusted for
pre-transplant characteristics, socioeconomic factors, and
relapse after HCT. When scores of QOL measures were
assessed on a continuous scale, HCT-CI scores of 0 vs. 1-2, vs.
3 were associated with impaired physical health as
evidences by decreasing means (SD) of 48.9 (10.4) vs. 47.2
(11.2) vs. 44.9 (10.4), respectively, of the physical component
score of the SF-36 (P ¼ 0.04). Other QOL measures were
assessed as dichotomized outcomes based on standard cut-
offs of the population norm. Higher HCT-CI scores were
signiﬁcantly associated with increased depression, increased
distress from cancer or its treatment, diminished social
support, and higher comorbidity burden among long-term
survivors (Table). HCT-CI scores were not associated with the
mental component of the SF-36, increased fatigue, or social
activities.
This is, to the best of our knowledge, the ﬁrst evidence
that pre-transplant comorbidities, captured by a prognostic
comorbidity index, were associated with long-term QOL
outcomes for survivors after allogeneic HCT. Prospective
studies are warranted to explore associations of comorbid-
ities with QOL early after HCT and to evaluate preventive or
rehabilitation interventions that might improve long-term
QOL for survivors, particularly those with high pretransplant
comorbidity burden.
